Loading video.
VIDEO: Nanomedicines consisting of one molecule of oligonucleotide and one or two
molecules of Y-shaped block copolymer(s), of which the size is approximately
18 nm and is in dynamic equilibrium with free Y-shaped. view more
Credit: 2021 Innovation Center of NanoMedicine
Summary
Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.
Chemically modified and double-stranded oligonucleotides dramatically enhanced the stability of the ultra-small nanomedicines in the blood circulation.
The ultra-small size allows for high permeability in cancer tissues by slipping through the cracks in tumor vasculatures and stromal tissues.
E-Mail
DURHAM, N.C. - A Duke-led team of scientists has developed a bio-compatible surgical patch that releases non-opioid painkillers directly to the site of a wound for days and then dissolves away.
The polymer patch provides a controlled release of a drug that blocks the enzyme COX-2 (cyclooxygenase-2,) which drives pain and inflammation. The study appears Jan. 10, 2021 in the
Journal of Controlled Release.
When they started We were making hernia meshes and different antimicrobial films, said Matthew Becker, the Hugo L. Blomquist professor chemistry at Duke, and last author on the paper. We thought you could potentially put pain drugs or anesthetics in the film if you just sew it in as you re stitching the person up, then you wouldn t necessarily have to prescribe any opioids, Becker said.
Published: Jan 06, 2021
Global Thin Film Drug Manufacturing Market: Snapshot
The thin film drugs were recorded with high market acceptance due to its ease of application and high effectiveness. Moreover, developed economies such as the U.S. and countries in Europe recorded significant sale of thin film drugs. Thin film drugs achieve the desired therapeutic results. Therefore, they have gained attention in the market as a potential treatment option. According to the research report, the global thin film drug manufacturing market is expected to be worth US$15,984.3 mn by the end of 2024 from US$7,337.8 mn in 2015. During the forecast years of 2016 and 2024, the global market is projected to exhibit a CAGR of 9.0%.
Researchers use new method to deliver anti-cancer drug to suppress tumor growth
Dec 17 2020
Targeting drugs to cancer tissues is a major challenge in cancer treatment. Mesenchymal stem cells (MSCs) are known for their ability to find and target tumor cells in the body, but using MSCs for drug delivery has been tricky, because upon loading with drugs, MSCs lose their viability and migratory ability. Now, researchers from Tokyo University of Science have successfully modified MSCs to deliver large quantities of anti-cancer drugs in a targeted manner to developing cancer cells.
As humans evolve, cancer also evolves in parallel, making the race for finding efficient treatment methods for cancer patients challenging and constant. In addition to designing drugs for treatment, the delivery of these drugs to targeted organs is also a major challenge faced by the cancer research community.
The bull s eye: New modified stem cells can deliver drugs specifically to tumor cells
As humans evolve, cancer also evolves in parallel, making the race for finding efficient treatment methods for cancer patients challenging and constant. In addition to designing drugs for treatment, the delivery of these drugs to targeted organs is also a major challenge faced by the cancer research community.
Many research groups have tried to develop techniques to efficiently deliver anti-cancer drugs to tumors. An interesting way utilizes a distinct group of cells in our body, the mesenchymal stem cells (MSCs), which have a special ability to find and move towards tumors. This means that theoretically, we can load these tumor-homing MSCs with anti-cancer drugs and use them to hinder cancer progression. However, pilot studies show that the anti-cancer drug loading capacity of MSCs is limited, and they tend to lose their ability to target and reach tumor cells upon drug loading.